Head and Neck Squamous Cell Carcinoma Clinical Trials in Wuhan
3 recruitingWuhan, China
Showing 1–3 of 3 trials
Recruiting
Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca1,145 enrolled305 locationsNCT06129864
Recruiting
Phase 3
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Locally Advanced Head and Neck Squamous Cell CarcinomaAged
Johnson & Johnson Enterprise Innovation Inc.500 enrolled189 locationsNCT04892173
Recruiting
Phase 2
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Cervical CancerHead and Neck Squamous Cell Carcinoma
AstraZeneca110 enrolled50 locationsNCT06535607